期刊
CELL METABOLISM
卷 31, 期 2, 页码 406-+出版社
CELL PRESS
DOI: 10.1016/j.cmet.2019.11.013
关键词
-
资金
- American Heart Association
- NIH [1K99DK115778, AI136715, DK108370, DK078772, DK068437, DK101251, R01AI089824, AI089824, DK116620, HL132412, HL087123]
- American Liver Foundation Liver Scholar Award
- American Society of Hematology
- American Heart Association [19CDA34660043]
- NIH-NHLBI [T32HL007343]
- MGH Research Scholars Program
- MyFirst Grant Associazione Italiana per la Ricerca Sul Cancro (AIRC) [16888]
- Ricerca Finalizzata Ministero della Salute [RF-2016-02364358]
- Ricerca Corrente Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
- European Union (EU) Programme Horizon 2020 [777377]
- NIH/National Institute of Diabetes and Digestive and Kidney Diseases Center grant [5P30DK063608]
Nonalcoholic steatohepatitis (NASH) is emerging as a leading cause of chronic liver disease. However, therapeutic options are limited by incomplete under-standing of the mechanisms of NASH fibrosis, which is mediated by activation of hepatic stellate cells (HSCs). In humans, human genetic studies have shown that hypomorphic variations in MERTK, encod-ing the macrophage c-mer tyrosine kinase (MerTK) receptor, provide protection against liver fibrosis, but the mechanisms remain unknown. We now show that holo- or myeloid-specific Mertk targeting in NASH mice decreases liver fibrosis, congruent with the human genetic data. Furthermore, ADAM metallo-peptidase domain 17 (ADAM17)-mediated MerTK cleavage in liver macrophages decreases during steatosis to NASH transition, and mice with a cleav-age-resistant MerTK mutant have increased NASH fibrosis. Macrophage MerTK promotes an ERK-TG931 pathway that activates HSCs and induces liver fibrosis. These data provide insights into the role of liver macrophages in NASH fibrosis and provide a plausible mechanism underlying MERTK as a genetic risk factor for NASH fibrosis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据